Laser Tissue Welding, Inc. is a privately owned biotherapeutic company located in Humble Texas, incorporated in Delaware in 2004. It is structured as a vertically integrated research, development, and manufacturing entity. At present the company focuses its research and product development on two patented and proprietary platforms:

  • Transparent bio-absorbable human albumin burns and chronic wound dressings that can be customized with growth factors and antibiotics.

MARKET PROBLEM AND OUR OPPORTUNITY: Hemostasis & bonding edges of human tissue is a vital step in all surgical procedures. In medicine today, surgeons suture or staple incisions, and tissue bonding is impaired by the foreign body reaction and ensuring tissue compression. Hemostasis or tissue sealing is usually achieved by burning tissues using thermal ablation (electrocautery, radio-frequency or ultrasonic energy), again impairing healing because of indiscriminate destruction of normal tissues which is usually followed by deformation and scaring, chronic pain and disability. Both joining and sealing technologies in current use are slow, tissue damaging and largely ineffective for a variety of tissue types such as liver, pancreas, kidney, spleen, neural tissues (nerves, spinal cord, brain) and bone. 

SOLUTION: Laser tissue welding (LTW) is platform technology with numerous applications of use. “An innovation of better solutions that meets new requirements, unarticulated needs, and addresses existing unmet clinical needsʺ. Laser tissue welding is transformational technology that can be used for over 3000 current surgical procedures because it provides quick and accurate hemostasis. It breaks a barrier and is lifesaving when used in surgical procedures on patients suffering from clotting deficiencies or on blood thinners who are at risk for bleeding to death on the operating table. LTW is specifically useful when dealing with solid visceral organs with soft friable jelly-like tissues, such as the liver, pancreas, spleen and kidney which cannot be sutured or sealed easily. It enables the surgeon to undertake resections in non-anatomical planes join and seal the parenchyma with minimal thermal damage. This creates a new genre or paradigm of innovative enhanced surgical capabilities for several hereto unmet clinical needs in orthopedics, dentistry, craniofacial surgery, neurosurgery, urology, oncology, plastic and trauma surgery. It is particularly well suited for minimally invasive, robotic and the advent of automated surgery. 

PRODUCT DEFINITION:  A diode laser is used to coagulate a human albumin-dye solder together with a solid transparent human albumin scaffold that together provides for quick, accurate hemostasis and sealing. The treatment process uses thermal energy created when a laser excites photosensitive dye molecules, to coagulate human serum albumin which transforms from a liquid to a solid instantly. Just point, aim and fuse. The energy is dissipated within the biomaterials, leaving native parenchyma unscathed. Fusion Rate: 1.57 sec/cm2. Sealing and joining of tissues is without the adverse effects of compression sutures, foreign animal and synthetic materials and without burning, all the while providing a biological human albumin scaffold for tissue regrowth, thereby sculpting tissues and salvaging organs. Benefits include a decrease in operating time, shorter recovery and hospital stay, reduced blood transfusion, reduced complications and overall decrease in health care costs. Recovery times are hastened with diminished pain, immobility and scar deformity. The innovation lies in the iterations and refinements across numerous cross disciplinary areas involving medical lasers, laser optics, biological human biomaterials and surgical procedural techniques. Surgical resection is curative when tumors are diagnosed at the T1 stage. Due to the increased application of abdominal imaging, there has been a concurrent downward stage migration of liver, pancreatic, and renal masses. Renal masses 4 cm or less account for the largest proportion of newly diagnosed renal tumors. Current pancreatic, liver and kidney surgical resections are fraught with the development of post-surgical bleeding, pancreatic, urine and bile leaks, fistulas, which are a significant cause of morbidity and mortality in postoperative patients.

It is an elegant disruptive and futuristic combination device which consists of an 810nm diode laser and two human albumin based biomaterials. Special areas of unmet clinical need addressed by this combination device are surgical interventions on solid visceral organs such as the liver and kidney involved in trauma, cancer and transplantation; and patients requiring low pressure surgical hemostasis while therapeutically anticoagulated or having hemodilutional or hypothermic coagulation failure. The benefits of this new paradigm are due to its ability to quickly repair and control hemorrhage, bile or urine with minimal thermal injury. These benefits include a decrease in operating time, ability to control bleeding instantly, decrease in morbidity and mortality, shorter hospital stay, decrease in healthcare costs; conservation of blood products by reducing transfusion requirements; and increase the donor pool for liver transplantation by enabling split liver transplantation. 

Laser Tissue Welding has completed development of a clinical device and has successfully completed a human feasibility clinical study in 2013. 


Grants and Awards:

Phase I Small Business Innovative Research (SBIR) Commercialization Grant award-National Institutes of Health.

2007-2008: Texas Emerging Technology Fund (TETF) awarded a research matching grant from the office of the Governor. 

2009-2010:  Qualifying Therapeutic Discovery Project Grant (QTDP) 

2010-2012: Phase II Small Business Innovative Research (SBIR) Commercialization Grant award- National Institutes of Health. (Hepatectomy application)

2012-2015Fast Track Small Business Innovative Research (SBIR) Commercialization Grant award- National Institutes of Health. (Robotically Assisted Laparoscopic Partial Nephrectomy)  

Disclosure: *The US Food and Drug Administration (FDA) has not approved the Laser Tissue Welding System for general use.

Latest News
Recent Articles
4/8/2012 6:36:51 AM
November 15, 2008: The Business Makers Interview
Episode 180: Flashback— Yasmin Wadia, Laser Tissue Welding Inc.
Russ Capper reports in from the Houston Technology Showcase with a discussion with Dr. Yasmin Wadia, inventor of a laser tissue welding device, a “point and shoot” process that fuses tissue and stops bleeding immediately. This sutureless process could change the future of surgery and recovery. Click to navigate
4/7/2012 10:18:14 AM
Dr. Yasmin Wadia honored as 'Woman Entrepreneur of the Year'
Four prominent Indian Americans were honoured for their entrepreneurship and community services by the Indo American Chamber of Commerce of Greater Houston (IACCGH).
The Hindu
RMR Media - You Tube - 7.17' to 7.30'

4/7/2012 10:09:11 AM
06/20/2011: Companies To Watch: Larta NIH-CAP 2010/11 Participant Laser Tissue Welding

Larta NIH-CAP 2010/11 Participant Laser Tissue Welding

Laser Tissue Welding (LTW), a current NIH Commercialization Assistant Program participant (NIH-CAP), is a privately owned biotherapeutic medical device company located in Humble Texas, and was founded and incorporated in Delaware in 2004. LTW’s innovation is a new paradigm in surgical care, an enabling combination surgical device that seals hemorrhage and fluid leaks accurately, instantly on demand without burning. The technology uses a diode laser and two human serum albumin biodegradable bio-materials to enable surgical interventions on vascular solid visceral organs as the liver, kidney and spleen and hemostasis in coagulopathic patients requiring surgery..Read more


11/20/2008 12:00:00 AM
Podcast: LTW Texas Life Sciences Conference Presentation
The Thursday Commercialization Forum showcased promising technologies from research institutions, a number of Texas’ most innovative and exciting life science companies, including finalist start-ups from the Emerging Technology Fund. Click to download.